NSI-189 vs P21
A side-by-side research comparison of NSI-189 and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NSI-189 | P21 |
|---|---|---|
| Full name | NSI-189 Phosphate (Neurogenic Compound) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | 366.4 Da | ~450 Da |
| Half-life | 18-22 hours | 4-6 hours |
| Bioavailability | High (oral) | Moderate (crosses BBB) |
| Typical dose | 40-80 mg | 50-100 mcg/kg |
| Frequency | Once daily | Daily |
| Route | Oral | Intranasal or Subcutaneous |
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.